SUPERNUS PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Payments to Acquire Marketable Securities of $340.67 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2022-11-09
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2022-09-30 was $134.16M, a 80.42% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2022-06-30 was $108.44M, a 5.05% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2022-03-31 was $98.06M, a 17.64% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2021-09-30 was $74.36M, a 2.56% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2020 was $95.89M, a 76.60% decline from fiscal 2019.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2019 was $409.71M, a 16.67% decline from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2018 was $491.65M, a 382.54% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2017 was $101.89M, a 115.12% increase from fiscal 2016.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | $134.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $242.60M derived: sum of 2 quarters · filed 2022-11-09 | $340.67M 10-Q · filed 2022-11-09 | |||||
| 2022-06-30 | $108.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $206.50M 10-Q · filed 2022-08-08 | ||||||
| 2022-03-31 | $98.06M 10-Q · filed 2022-05-12 | |||||||
| 2021-09-30 | $74.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $188.57M derived: sum of 2 quarters · filed 2022-11-09 | $307.63M 10-Q · filed 2022-11-09 | $315.63M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $114.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $233.27M 10-Q · filed 2022-08-08 | $241.27M derived: sum of 3 quarters · filed 2022-08-08 | $313.78M derived: sum of 4 quarters · filed 2022-08-08 | ||||
| 2021-03-31 | $119.06M 10-Q · filed 2022-05-12 | $127.06M derived: sum of 2 quarters · filed 2022-05-12 | $199.57M derived: sum of 3 quarters · filed 2022-05-12 | $199.57M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $80.51M derived: sum of 2 quarters · filed 2021-11-05 | $80.51M derived: sum of 3 quarters · filed 2021-11-05 | $95.89M 10-K · filed 2021-03-08 | ||||
| 2020-09-30 | $72.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $72.51M derived: sum of 2 quarters · filed 2021-11-05 | $87.89M 10-Q · filed 2021-11-05 | $136.48M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $15.38M 10-Q · filed 2021-08-06 | $63.97M derived: sum of 3 quarters · filed 2021-08-06 | $160.16M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $15.38M 10-Q · filed 2021-05-07 | $63.97M derived: sum of 2 quarters · filed 2021-05-07 | $160.16M derived: sum of 3 quarters · filed 2021-05-07 | $274.92M derived: sum of 4 quarters · filed 2021-05-07 | ||||
| 2019-12-31 | $48.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $144.78M derived: sum of 2 quarters · filed 2021-03-08 | $259.54M derived: sum of 3 quarters · filed 2021-03-08 | $409.71M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $96.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $210.95M derived: sum of 2 quarters · filed 2020-11-06 | $361.12M 10-Q · filed 2020-11-06 | $361.12M derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2019-06-30 | $114.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $264.93M 10-Q · filed 2020-08-17 | $264.93M derived: sum of 3 quarters · filed 2021-03-08 | $264.93M derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2019-03-31 | $150.17M 10-Q · filed 2020-05-15 | $150.17M derived: sum of 2 quarters · filed 2021-03-08 | $150.17M derived: sum of 3 quarters · filed 2021-03-08 | $584.06M derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | -$1.00K derived: sum of 2 quarters · filed 2021-03-08 | $433.90M derived: sum of 3 quarters · filed 2021-03-08 | $491.65M 10-K · filed 2021-03-08 | ||||
| 2018-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $433.90M derived: sum of 2 quarters · filed 2019-11-08 | $491.65M 10-Q · filed 2019-11-08 | $514.61M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $433.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $491.65M 10-Q · filed 2019-08-09 | $514.61M derived: sum of 3 quarters · filed 2020-02-28 | $545.08M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $57.76M 10-Q · filed 2019-05-10 | $80.71M derived: sum of 2 quarters · filed 2020-02-28 | $111.18M derived: sum of 3 quarters · filed 2020-02-28 | $137.45M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $22.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $53.42M derived: sum of 2 quarters · filed 2020-02-28 | $79.70M derived: sum of 3 quarters · filed 2020-02-28 | $101.89M 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $30.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $56.74M derived: sum of 2 quarters · filed 2018-11-09 | $78.94M 10-Q · filed 2018-11-09 | $95.11M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $26.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $48.47M 10-Q · filed 2018-08-09 | $64.64M derived: sum of 3 quarters · filed 2019-03-01 | $72.79M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $22.19M 10-Q · filed 2018-05-10 | $38.36M derived: sum of 2 quarters · filed 2019-03-01 | $46.52M derived: sum of 3 quarters · filed 2019-03-01 | $52.22M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $16.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $24.32M derived: sum of 2 quarters · filed 2019-03-01 | $30.03M derived: sum of 3 quarters · filed 2019-03-01 | $47.36M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $8.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $13.86M derived: sum of 2 quarters · filed 2017-11-09 | $31.19M 10-Q · filed 2017-11-09 | $43.11M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $5.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $23.04M 10-Q · filed 2017-08-03 | $23.69M 10-Q · filed 2016-08-05 | $34.96M derived: sum of 3 quarters · filed 2018-03-01 | $51.97M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | $17.34M 10-Q · filed 2017-05-09 | $17.99M 10-Q · filed 2016-05-10 | $29.25M derived: sum of 2 quarters · filed 2018-03-01 | $46.27M derived: sum of 3 quarters · filed 2018-03-01 | $63.23M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $11.92M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $28.93M derived: sum of 2 quarters · filed 2018-03-01 | $45.89M derived: sum of 3 quarters · filed 2018-03-01 | $63.86M 10-K · filed 2018-03-01 | $63.20M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | $17.02M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $33.98M derived: sum of 2 quarters · filed 2017-01-23 | $51.94M 10-Q/A · filed 2017-01-20 | $51.29M 10-Q · filed 2015-11-09 | $70.64M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $16.96M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | $34.93M 10-Q/A · filed 2017-01-23 | $34.27M 10-Q · filed 2015-08-07 | $53.62M derived: sum of 3 quarters · filed 2017-03-16 | $68.29M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $17.97M 10-Q/A · filed 2017-01-20 | $17.32M 10-Q · filed 2015-05-06 | $36.66M derived: sum of 2 quarters · filed 2017-03-16 | $51.33M derived: sum of 3 quarters · filed 2017-03-16 | $61.82M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $18.70M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $33.36M derived: sum of 2 quarters · filed 2017-03-16 | $43.86M derived: sum of 3 quarters · filed 2017-03-16 | $53.26M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $14.66M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $25.16M derived: sum of 2 quarters · filed 2017-01-20 | $34.57M 10-Q/A · filed 2017-01-20 | $41.16M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2014-06-30 | $10.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $19.90M 10-Q · filed 2015-08-07 | $26.50M derived: sum of 3 quarters · filed 2017-01-20 | $44.47M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2014-03-31 | $9.41M 10-Q · filed 2015-05-06 | $16.00M derived: sum of 2 quarters · filed 2017-01-20 | $33.97M derived: sum of 3 quarters · filed 2017-01-20 | $79.33M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2013-12-31 | $6.60M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $24.56M derived: sum of 2 quarters · filed 2017-01-20 | $69.92M derived: sum of 3 quarters · filed 2017-01-20 | $85.57M 10-K/A · filed 2017-01-20 | ||||
| 2013-09-30 | $17.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $63.33M derived: sum of 2 quarters · filed 2014-11-12 | $78.97M 10-Q · filed 2014-11-12 | $120.17M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $45.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $61.00M 10-Q · filed 2014-08-12 | $102.20M derived: sum of 3 quarters · filed 2015-03-12 | $121.85M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $15.64M 10-Q · filed 2014-05-13 | $56.84M derived: sum of 2 quarters · filed 2015-03-12 | $76.49M derived: sum of 3 quarters · filed 2015-03-12 | $91.51M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $41.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $60.85M derived: sum of 2 quarters · filed 2015-03-12 | $75.87M derived: sum of 3 quarters · filed 2015-03-12 | $97.67M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $19.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $34.67M derived: sum of 2 quarters · filed 2013-11-13 | $56.48M 10-Q · filed 2013-11-13 | $56.48M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2012-06-30 | $15.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $36.82M 10-Q · filed 2013-08-14 | $36.82M derived: sum of 3 quarters · filed 2014-03-21 | $36.82M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2012-03-31 | $21.81M 10-Q · filed 2013-05-15 | $21.81M derived: sum of 2 quarters · filed 2014-03-21 | $21.81M derived: sum of 3 quarters · filed 2014-03-21 | $25.85M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $0.00 derived: sum of 2 quarters · filed 2014-03-21 | $4.04M derived: sum of 3 quarters · filed 2014-03-21 | $17.89M 10-K · filed 2014-03-21 | ||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $4.04M derived: sum of 2 quarters · filed 2012-11-02 | $17.89M 10-Q · filed 2012-11-02 | |||||
| 2011-06-30 | $4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $17.89M 10-Q · filed 2012-08-13 | ||||||
| 2011-03-31 | $13.85M 10-Q · filed 2012-06-08 | |||||||
| 2010-12-31 | $32.78M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |